These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10339605)

  • 1. Induction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinases.
    Park BW; O'Rourke DM; Wang Q; Davis JG; Post A; Qian X; Greene MI
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6434-8. PubMed ID: 10339605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained mitogen-activated protein kinase activation is induced by transforming erbB receptor complexes.
    Wu CJ; Qian X; O'Rourke DM
    DNA Cell Biol; 1999 Oct; 18(10):731-41. PubMed ID: 10541432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LAR-PTPase cDNA transfection suppression of tumor growth of neu oncogene-transformed human breast carcinoma cells.
    Zhai Y; Wirth J; Kang S; Welsch CW; Esselman WJ
    Mol Carcinog; 1995 Oct; 14(2):103-10. PubMed ID: 7576097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
    Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin.
    Xu FJ; Boyer CM; Bae DS; Wu S; Greenwald M; O'Briant K; Yu YH; Mills GB; Bast RC
    Int J Cancer; 1994 Oct; 59(2):242-7. PubMed ID: 7927925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural insights into the down-regulation of overexpressed p185(her2/neu) protein of transformed cells by the antibody chA21.
    Zhou H; Zha Z; Liu Y; Zhang H; Zhu J; Hu S; Shen G; Cheng L; Niu L; Greene MI; Teng M; Liu J
    J Biol Chem; 2011 Sep; 286(36):31676-83. PubMed ID: 21680730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Cbl is a suppressor of the neu oncogene.
    Levkowitz G; Oved S; Klapper LN; Harari D; Lavi S; Sela M; Yarden Y
    J Biol Chem; 2000 Nov; 275(45):35532-9. PubMed ID: 10940298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.
    Lenferink AE; Simpson JF; Shawver LK; Coffey RJ; Forbes JT; Arteaga CL
    Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9609-14. PubMed ID: 10931950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of tyrosine phosphorylation of p185(c-erbB2/neu) in tumorigenicity induced by X-rays and the neu oncogene in human breast epithelial cells.
    Kang KS; Sun W; Nomata K; Morita I; Cruz A; Liu CJ; Trosko JE; Chang CC
    Mol Carcinog; 1998 Apr; 21(4):225-33. PubMed ID: 9585252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells.
    Romieu-Mourez R; Landesman-Bollag E; Seldin DC; Sonenshein GE
    Cancer Res; 2002 Nov; 62(22):6770-8. PubMed ID: 12438279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The extracellular domain of p185(c-neu) induces density-dependent inhibition of cell growth in malignant mesothelioma cells and reduces growth of mesothelioma in vivo.
    Yoneda T; Kumagai T; Nagatomo I; Furukawa M; Yamane H; Hoshino S; Mori M; Takeda Y; Horai T; Nishida S; Watanabe D; Kijima T; Yoshida M; Osaki T; Tachibana I; Greene MI; Kawase I
    DNA Cell Biol; 2006 Sep; 25(9):530-40. PubMed ID: 16989576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Epstein-Barr virus nuclear antigen-1 may act as a transforming suppressor of the HER2/neu oncogene.
    Chuang TC; Way TD; Lin YS; Lee YC; Law SL; Kao MC
    FEBS Lett; 2002 Dec; 532(1-2):135-42. PubMed ID: 12459478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors.
    Alaoui-Jamali MA; Song DJ; Benlimame N; Yen L; Deng X; Hernandez-Perez M; Wang T
    Cancer Res; 2003 Jul; 63(13):3764-74. PubMed ID: 12839972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Domain-specific interactions between the p185(neu) and epidermal growth factor receptor kinases determine differential signaling outcomes.
    Qian X; O'Rourke DM; Fei Z; Zhang HT; Kao CC; Greene MI
    J Biol Chem; 1999 Jan; 274(2):574-83. PubMed ID: 9872991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein.
    Qian X; O'Rourke DM; Zhao H; Greene MI
    Oncogene; 1996 Nov; 13(10):2149-57. PubMed ID: 8950982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p66Shc isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression.
    Xie Y; Hung MC
    Biochem Biophys Res Commun; 1996 Apr; 221(1):140-5. PubMed ID: 8660324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
    Menendez JA; Mehmi I; Verma VA; Teng PK; Lupu R
    Mol Carcinog; 2004 Nov; 41(3):164-78. PubMed ID: 15390078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
    Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
    Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation.
    Galang CK; García-Ramírez J; Solski PA; Westwick JK; Der CJ; Neznanov NN; Oshima RG; Hauser CA
    J Biol Chem; 1996 Apr; 271(14):7992-8. PubMed ID: 8626480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.